FluoGuide is shortlisted for EU grant

Report this content

COPENHAGEN, Denmark, 24 March 2020 - The European Innovation Council (EIC) has shortlisted 100 companies including FluoGuide for EIC grant.

The European Commission has shortlisted over 100 game-changing ideas from across Europe with high chance of being granted EIC support. The EU’s research and innovation program (funded by Horizon 2020) has among other proposals selected FluoGuide. The information from EU is available here (https://ec.europa.eu/info/news/european-innovation-council-pilot-eu344-million-107-visionary-start-ups-smes-and-researchers-2020-mar-12_en). FluoGuide will updated information, including the amount, when the final result of the evaluation is completed which is anticipated during the next 4 months.

The current tough humanitarian and economic situation is not as of today expected to have any specific impact on our timelines in FluoGuide. We are, as everyone else, monitoring the situation carefully as this can change overnight as for any current business. We have already before the start of the current situation applied for relevant grants and will continue to do so.

For further information, please contact:
Morten Albrechtsen, CEO
M: +45 24 25 62 66


About FluoGuide 
FluoGuide A/S (Spotlight Stock Market: FLUO:SS) provides solutions for maximizing surgical outcome through intelligent targeting. FluoGuide’s first product FG001 increases precision in cancer surgery by lighting up the cancer and its invasive growth into the surrounding tissue. FG001 is expected to reduce suffering for the patients and increase the likelihood of cure. It can also reduce costs for the health care system for the benefit of society. FluoGuide focuses on demonstrating the effect of FG001 in patients by conducting a human proof-of-concept clinical trial and expects to announce the first result of this study during first half of 2020.


About FG001
FG001, FluoGuide’s first product, lights up the cancer and its invasive growth into the surrounding tissue. It helps the surgeon remove the entire tumor during surgery and increases the chance for complete cure of the patient. The task for the surgeon is simply to "turn the lights on and see the entire tumor". The solution helps surgeons remove a minimal amount of normal tissue while also reducing the risk of leaving cancer tissue behind. This reduces the suffering of the patient and increases the likelihood of cure, and also reduces costs for the health care system. FG001 is currently prepared for a proof-of-concept clinical study.



About EIC grant 

The EIC Accelerator (SME Instrument) is part of the European Innovation Council (EIC) pilot that supports top class innovators, entrepreneurs and small companies with funding opportunities and acceleration services. The main focus of the EIC Accelerator (SME Instrument), is on market-creating innovations that shape new markets and generate jobs, growth and higher standards of living.